Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alovudine Medivir.

Stefano Rusconi1

  • 1Istituto di Malattie Infettive e Tropicali Università degli Studi Ospedale Luigi Sacco via GB Grassi 74, 20157 Milano, Italy. rusconi@mailserver.unimi.it

Current Opinion in Investigational Drugs (London, England : 2000)
|April 3, 2003
PubMed
Summary

Medivir is developing alovudine, an anti-human immunodeficiency virus (HIV) compound for treating drug-resistant HIV infection. A completed phase IIa trial evaluated this potential new therapy in patients with multiresistant HIV.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort.

The Journal of antimicrobial chemotherapy·2026
Same author

Early Combination Antiretroviral Therapy Initiation During Primary HIV Infection Restricts HIV Reservoirs and Gut-Driven Inflammation but Fails to Rewire the Systemic Cytokine Landscape.

Open forum infectious diseases·2026
Same author

Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes.

The Journal of antimicrobial chemotherapy·2026
Same author

Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/ml and history of K103N mutation.

AIDS (London, England)·2026
Same author

Proportion of newly diagnosed persons with HIV with HIV-RNA greater than/equal to 500 000 copies/mL in 2018-2023 in Italy: data from the ICONA Foundation Cohort Study.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: the multicentre retrospective CEFI-BAC study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2025

Area of Science:

  • Antiviral drug development
  • HIV/AIDS research
  • Clinical pharmacology

Background:

  • Drug-resistant human immunodeficiency virus (HIV) presents a significant clinical challenge.
  • Novel therapeutic agents are needed to overcome resistance mechanisms in HIV infection.

Purpose of the Study:

  • To evaluate the safety and tolerability of alovudine in patients with multiresistant HIV.
  • To assess the potential of alovudine as a treatment for drug-resistant HIV infection.

Main Methods:

  • A phase IIa clinical trial was conducted.
  • The study involved patients diagnosed with multiresistant HIV.

Main Results:

  • The phase IIa trial was initiated in October 2001 and completed by July 2002.
  • Results regarding efficacy and specific safety profiles are pending further analysis.

Conclusions:

  • Alovudine is under investigation as a potential treatment for drug-resistant HIV.
  • The completion of the phase IIa trial represents a step in evaluating alovudine's therapeutic potential.

Related Experiment Videos